Review



quantitative high-resolution computed tomography (hrct) metrics  (Imbio LLC)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Imbio LLC quantitative high-resolution computed tomography (hrct) metrics
    Patients’ clinical characteristics and <t> high-resolution computed tomography metrics </t> at baseline.
    Quantitative High Resolution Computed Tomography (Hrct) Metrics, supplied by Imbio LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/quantitative+high-resolution+computed+tomography+(hrct)+metrics/quantitative+high+resolution+computed+tomography++hrct++metrics/pmc10588799-37-14-21
    Average 90 stars, based on 1 article reviews
    quantitative high-resolution computed tomography (hrct) metrics - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Weak to no correlation between quantitative high-resolution computed tomography metrics and lung function change in fibrotic diseases"

    Article Title: Weak to no correlation between quantitative high-resolution computed tomography metrics and lung function change in fibrotic diseases

    Journal: ERJ Open Research

    doi: 10.1183/23120541.00210-2023

    Patients’ clinical characteristics and high-resolution computed tomography metrics at baseline.
    Figure Legend Snippet: Patients’ clinical characteristics and high-resolution computed tomography metrics at baseline.

    Techniques Used: Computed Tomography

    Forest plot for the Spearman correlation coefficient with 95% confidence intervals between forced vital capacity (FVC) and high-resolution computed tomography (HRCT) metrics at baseline. qILD: quantification of interstitial lung disease; PFD: pirfenidone.
    Figure Legend Snippet: Forest plot for the Spearman correlation coefficient with 95% confidence intervals between forced vital capacity (FVC) and high-resolution computed tomography (HRCT) metrics at baseline. qILD: quantification of interstitial lung disease; PFD: pirfenidone.

    Techniques Used: Computed Tomography

    Forest plot for the Spearman correlation coefficient with 95% confidence intervals between forced vital capacity (FVC) and high-resolution computed tomography (HRCT) metrics. qILD: quantification of interstitial lung disease; PFD: pirfenidone.
    Figure Legend Snippet: Forest plot for the Spearman correlation coefficient with 95% confidence intervals between forced vital capacity (FVC) and high-resolution computed tomography (HRCT) metrics. qILD: quantification of interstitial lung disease; PFD: pirfenidone.

    Techniques Used: Computed Tomography

    Scatterplot with a smooth line using a generalised additive model between baseline high-resolution computed tomography (HRCT) metrics and forced vital capacity (FVC) slope. The shaded area represents 95% confidence interval of the smooth line. qILD: quantification of interstitial lung disease; PFD: pirfenidone.
    Figure Legend Snippet: Scatterplot with a smooth line using a generalised additive model between baseline high-resolution computed tomography (HRCT) metrics and forced vital capacity (FVC) slope. The shaded area represents 95% confidence interval of the smooth line. qILD: quantification of interstitial lung disease; PFD: pirfenidone.

    Techniques Used: Computed Tomography

    Adjusted R 2 of high-resolution computed tomography (HRCT) metrics in predicting forced vital capacity (FVC) slope after adjusting baseline clinical characteristics. a) Tocilizumab phase 3 in systemic sclerosis (SSc) (n=86); two patients were not included in the analysis as they did not have post-baseline measurements; b) zinpentraxin alfa phase 2 in idiopathic pulmonary fibrosis (IPF) (n=39); c) lebrikizumab phase 2 in IPF cohort A (n=38); d) lebrikizumab phase 2 in IPF cohort B (n=106). Each HRCT metric was sorted based on their adjusted R 2 level. The dashed line is the adjusted R 2 from the base model, and each dot represents the adjusted R 2 from the base model with the added HRCT metric. Base model: FVC slope ∼ baseline FVC + sex + age + height; added model: FVC slope ∼ baseline FVC + sex + age + height + HRCT. qILD: quantification of interstitial lung disease; PFD: pirfenidone.
    Figure Legend Snippet: Adjusted R 2 of high-resolution computed tomography (HRCT) metrics in predicting forced vital capacity (FVC) slope after adjusting baseline clinical characteristics. a) Tocilizumab phase 3 in systemic sclerosis (SSc) (n=86); two patients were not included in the analysis as they did not have post-baseline measurements; b) zinpentraxin alfa phase 2 in idiopathic pulmonary fibrosis (IPF) (n=39); c) lebrikizumab phase 2 in IPF cohort A (n=38); d) lebrikizumab phase 2 in IPF cohort B (n=106). Each HRCT metric was sorted based on their adjusted R 2 level. The dashed line is the adjusted R 2 from the base model, and each dot represents the adjusted R 2 from the base model with the added HRCT metric. Base model: FVC slope ∼ baseline FVC + sex + age + height; added model: FVC slope ∼ baseline FVC + sex + age + height + HRCT. qILD: quantification of interstitial lung disease; PFD: pirfenidone.

    Techniques Used: Computed Tomography

    Related Articles

    Computed Tomography:

    Article Title: Weak to no correlation between quantitative high-resolution computed tomography metrics and lung function change in fibrotic diseases
    Article Snippet: The purpose of the present study was to explore the prognostic value of quantitative high-resolution computed tomography (HRCT) metrics derived by Imbio lung texture analysis (LTA) tool in predicting FVC slope.

    Derivative Assay:

    Article Title: Weak to no correlation between quantitative high-resolution computed tomography metrics and lung function change in fibrotic diseases
    Article Snippet: The purpose of the present study was to explore the prognostic value of quantitative high-resolution computed tomography (HRCT) metrics derived by Imbio lung texture analysis (LTA) tool in predicting FVC slope.



    Similar Products

    quantitative high-resolution computed tomography (hrct) metrics  (Imbio LLC)
    90
    Imbio LLC quantitative high-resolution computed tomography (hrct) metrics
    Patients’ clinical characteristics and <t> high-resolution computed tomography metrics </t> at baseline.
    Quantitative High Resolution Computed Tomography (Hrct) Metrics, supplied by Imbio LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/quantitative+high-resolution+computed+tomography+(hrct)+metrics/quantitative+high+resolution+computed+tomography++hrct++metrics/pmc10588799-37-14-21
    Average 90 stars, based on 1 article reviews
    quantitative high-resolution computed tomography (hrct) metrics - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Patients’ clinical characteristics and high-resolution computed tomography metrics at baseline.

    Journal: ERJ Open Research

    Article Title: Weak to no correlation between quantitative high-resolution computed tomography metrics and lung function change in fibrotic diseases

    doi: 10.1183/23120541.00210-2023

    Figure Lengend Snippet: Patients’ clinical characteristics and high-resolution computed tomography metrics at baseline.

    Article Snippet: The purpose of the present study was to explore the prognostic value of quantitative high-resolution computed tomography (HRCT) metrics derived by Imbio lung texture analysis (LTA) tool in predicting FVC slope.

    Techniques: Computed Tomography

    Forest plot for the Spearman correlation coefficient with 95% confidence intervals between forced vital capacity (FVC) and high-resolution computed tomography (HRCT) metrics at baseline. qILD: quantification of interstitial lung disease; PFD: pirfenidone.

    Journal: ERJ Open Research

    Article Title: Weak to no correlation between quantitative high-resolution computed tomography metrics and lung function change in fibrotic diseases

    doi: 10.1183/23120541.00210-2023

    Figure Lengend Snippet: Forest plot for the Spearman correlation coefficient with 95% confidence intervals between forced vital capacity (FVC) and high-resolution computed tomography (HRCT) metrics at baseline. qILD: quantification of interstitial lung disease; PFD: pirfenidone.

    Article Snippet: The purpose of the present study was to explore the prognostic value of quantitative high-resolution computed tomography (HRCT) metrics derived by Imbio lung texture analysis (LTA) tool in predicting FVC slope.

    Techniques: Computed Tomography

    Forest plot for the Spearman correlation coefficient with 95% confidence intervals between forced vital capacity (FVC) and high-resolution computed tomography (HRCT) metrics. qILD: quantification of interstitial lung disease; PFD: pirfenidone.

    Journal: ERJ Open Research

    Article Title: Weak to no correlation between quantitative high-resolution computed tomography metrics and lung function change in fibrotic diseases

    doi: 10.1183/23120541.00210-2023

    Figure Lengend Snippet: Forest plot for the Spearman correlation coefficient with 95% confidence intervals between forced vital capacity (FVC) and high-resolution computed tomography (HRCT) metrics. qILD: quantification of interstitial lung disease; PFD: pirfenidone.

    Article Snippet: The purpose of the present study was to explore the prognostic value of quantitative high-resolution computed tomography (HRCT) metrics derived by Imbio lung texture analysis (LTA) tool in predicting FVC slope.

    Techniques: Computed Tomography

    Scatterplot with a smooth line using a generalised additive model between baseline high-resolution computed tomography (HRCT) metrics and forced vital capacity (FVC) slope. The shaded area represents 95% confidence interval of the smooth line. qILD: quantification of interstitial lung disease; PFD: pirfenidone.

    Journal: ERJ Open Research

    Article Title: Weak to no correlation between quantitative high-resolution computed tomography metrics and lung function change in fibrotic diseases

    doi: 10.1183/23120541.00210-2023

    Figure Lengend Snippet: Scatterplot with a smooth line using a generalised additive model between baseline high-resolution computed tomography (HRCT) metrics and forced vital capacity (FVC) slope. The shaded area represents 95% confidence interval of the smooth line. qILD: quantification of interstitial lung disease; PFD: pirfenidone.

    Article Snippet: The purpose of the present study was to explore the prognostic value of quantitative high-resolution computed tomography (HRCT) metrics derived by Imbio lung texture analysis (LTA) tool in predicting FVC slope.

    Techniques: Computed Tomography

    Adjusted R 2 of high-resolution computed tomography (HRCT) metrics in predicting forced vital capacity (FVC) slope after adjusting baseline clinical characteristics. a) Tocilizumab phase 3 in systemic sclerosis (SSc) (n=86); two patients were not included in the analysis as they did not have post-baseline measurements; b) zinpentraxin alfa phase 2 in idiopathic pulmonary fibrosis (IPF) (n=39); c) lebrikizumab phase 2 in IPF cohort A (n=38); d) lebrikizumab phase 2 in IPF cohort B (n=106). Each HRCT metric was sorted based on their adjusted R 2 level. The dashed line is the adjusted R 2 from the base model, and each dot represents the adjusted R 2 from the base model with the added HRCT metric. Base model: FVC slope ∼ baseline FVC + sex + age + height; added model: FVC slope ∼ baseline FVC + sex + age + height + HRCT. qILD: quantification of interstitial lung disease; PFD: pirfenidone.

    Journal: ERJ Open Research

    Article Title: Weak to no correlation between quantitative high-resolution computed tomography metrics and lung function change in fibrotic diseases

    doi: 10.1183/23120541.00210-2023

    Figure Lengend Snippet: Adjusted R 2 of high-resolution computed tomography (HRCT) metrics in predicting forced vital capacity (FVC) slope after adjusting baseline clinical characteristics. a) Tocilizumab phase 3 in systemic sclerosis (SSc) (n=86); two patients were not included in the analysis as they did not have post-baseline measurements; b) zinpentraxin alfa phase 2 in idiopathic pulmonary fibrosis (IPF) (n=39); c) lebrikizumab phase 2 in IPF cohort A (n=38); d) lebrikizumab phase 2 in IPF cohort B (n=106). Each HRCT metric was sorted based on their adjusted R 2 level. The dashed line is the adjusted R 2 from the base model, and each dot represents the adjusted R 2 from the base model with the added HRCT metric. Base model: FVC slope ∼ baseline FVC + sex + age + height; added model: FVC slope ∼ baseline FVC + sex + age + height + HRCT. qILD: quantification of interstitial lung disease; PFD: pirfenidone.

    Article Snippet: The purpose of the present study was to explore the prognostic value of quantitative high-resolution computed tomography (HRCT) metrics derived by Imbio lung texture analysis (LTA) tool in predicting FVC slope.

    Techniques: Computed Tomography